Anti-CD38 antibody for refractory acquired hemophilia A

Wei Liu; Jiaying Liu; Feng Xue; Renchi Yang; Lei Zhang

doi:10.1016/j.jtha.2023.03.010

Anti-CD38 antibody for refractory acquired hemophilia A

J Thromb Haemost. 2023 Jun;21(6):1515-1518. doi: 10.1016/j.jtha.2023.03.010. Epub 2023 Mar 20.

Authors

Wei Liu¹, Jiaying Liu¹, Feng Xue¹, Renchi Yang¹, Lei Zhang²

Affiliations

¹ State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, China.
² State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin Key Laboratory of Gene Therapy for Blood Diseases, CAMS Key Laboratory of Gene Therapy for Blood Diseases, Tianjin, China; Tianjin Institutes of Health Science, Tianjin, China. Electronic address: zhanglei1@ihcams.ac.cn.

PMID: 36940802
DOI: 10.1016/j.jtha.2023.03.010

Abstract

Patients with acquired hemophilia A (AHA) are prone to bleeding symptoms due to decrease in factor (F)VIII activity caused by FVIII antibodies. Risk of severe bleeding in AHA is higher than that of hereditary hemophilia, so clearance of FVIII inhibitors is necessary for treatment, especially in refractory AHA. Daratumumab is currently a popular monoclonal antibody for clearing plasma cells and antibodies and is often used in multiple myeloma. Based on this, we report, for the first time, that 4 patients with AHA who were refractory to first- and second-line therapy were treated with daratumumab and achieved good responses. None of our 4 patients developed serious infections. Thus, we provide a new approach for treating refractory AHA.

Keywords: FVIII inhibitor; acquired hemophilia A; daratumumab; factor VIII; immunosuppression therapy.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Factor VIII
Hemophilia A* / diagnosis
Hemophilia A* / drug therapy
Hemorrhage / complications
Humans

Substances

Factor VIII

Supplementary concepts

Factor 8 deficiency, acquired